June 4, 2011

Sanofi's Investigational Semuloparin in Cancer Patients initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism

- Results of Phase III SAVE-ONCO study selected for “Best of ASCO 2011” -
- Venous Thrombo-embolism Affects Up to 1 in 5 Cancer Patients and Chemotherapy Further Increases this Risk -

 

Sanofi’s Investigational Semuloparin in Cancer Patients initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism
- Results of Phase III SAVE-ONCO study selected for “Best of ASCO 2011” -
- Venous Thrombo-embolism Affects Up to 1 in 5 Cancer Patients and Chemotherapy Further Increases this Risk -

Paris, France – June 4, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)- related death by 64%i, meeting the study primary endpoint (respectively 1.2% and 3.4% for semuloparin and placebo HR 0.36 95% CI (0.21-0.60)), p< 0.0001). Semuloparin reduced the risk of this type of blood clots without increasing the incidence of major bleeding over placebo (1.2% vs. 1.1%) i. The SAVE-ONCO study results were presented today in an oral presentation at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, and are selected for the Best of ASCO*.